AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Radiofrequency versus Ultrasound Renal Denervation as Adjunctive Therapy for Hypertension: A Network Meta-Analysis of Second-Generation Sham-Controlled Randomized Trials

By Marlecha P, Zhang J, Laffin LJ et al.

Background: Radiofrequency (RF) or ultrasound (US) mediated renal denervation (RDN) have emerged as catheter-based device treatment for resistant hypertension. Both approaches effectively reduce blood pressure (BP) compared with sham, however, there are no randomized trials comparing the two modalities. Methods: A frequentist random-effects network meta-analysis was performed using second-generation sham-controlled randomized trials evaluating RDN in patients receiving antihypertensive medications. Five trials were included (SPYRAL HTN-ON MED Pilot, RADIANCE-HTN TRIO, REQUIRE, RADIOSOUND-HTN, and IBERIS-HTN; n=676). The primary outcome was change in 24-hour ambulatory systolic BP (SBP). Secondary outcomes included daytime SBP, nighttime SBP, office SBP, and 24-hour ambulatory diastolic BP (DBP). Results: In the primary analysis, neither RF (MD -5.3 mmHg, 95% CI -11.9 to 1.3) nor ultrasound RDN (MD -5.6 mmHg, 95% CI -12.4 to 1.2) reached significance versus sham, with high heterogeneity (I ² =82.5%) and significant network inconsistency (p<0.0001), driven by the REQUIRE trial. The RF versus ultrasound difference was 0.3 mmHg (95% CI -7.5 to 8.1), indicating equivalence. On sensitivity analysis excluding REQUIRE, both RF (MD -6.3 mmHg, p=0.048) and ultrasound (MD -8.6 mmHg, p=0.029) were significant. For secondary outcomes, RF significantly reduced nighttime SBP (MD -8.9 mmHg, p<0.0001), office SBP (MD -7.5 mmHg, p<0.0001), and 24-hour DBP (MD -4.4 mmHg, p<0.0001) with zero heterogeneity. Ultrasound significantly reduced daytime SBP (MD -9.1 mmHg, p=0.029). Conclusions: In patients on antihypertensive therapy, the efficacy of BP reduction was similar between RF and US renal denervation in second-generation sham-controlled randomized trials with neither modality being superior. When methodologically robust trials are considered, second-generation RDN demonstrates consistent BP reduction as adjunct to antihypertensive therapy, with no basis for preferring one modality over the other.

doi.org/10.1161/circ.154.suppl_1.15480Interventions

AgingResearch.News